Emil Novruzov

Dr. Emil Novruzov

University Hospital Duesseldorf
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KDKatharina Dendl
Katharina Dendl
SKStefan Alexander Körber
Stefan Alexander Körber
CKClemens Kratochwil
Clemens Kratochwil
JCJens Cardinale
Jens Cardinale
RFRebecca Finck
Rebecca Finck
Frederik L. GieselFrederik L. Giesel
Frederik L. Giesel
A fibroblast activation protein (FAP) is an atypical type II transmembrane serine protease with both endopeptidase and post-proline dipeptidyl peptidase activity. FAP is overexpressed in cancer-associated fibroblasts (CAFs), which are found in most epithelial tumors. CAFs have been implicated in promoting tumor cell invasion, angiogenesis and growth and their presence correlates with a poor prognosis. However, FAP can generally be found during the remodeling of the extracellular matrix and therefore can be detected in wound healing and benign diseases. For instance, chronic inflammation, arthritis, fibrosis and ischemic heart tissue after a myocardial infarction are FAP-positive diseases. Therefore, quinoline-based FAP inhibitors (FAPIs) bind with a high affinity not only to tumors but also to a variety of benign pathologic processes. When these inhibitors are radiolabeled with positron emitting radioisotopes, they provide new diagnostic and prognostic tools as well as insights into the role of the microenvironment in a disease. In this respect, they deliver additional information beyond what is afforded by conventional FDG PET scans that typically report on glucose uptake. Thus, FAP ligands are considered to be highly promising novel tracers that offer a new diagnostic and theranostic potential in a variety of diseases.

16 July 2024 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
RBRichard P. Baum
Richard P. Baum
Emil NovruzovEmil Novruzov
Emil Novruzov
TZTianzhi Zhao
Tianzhi Zhao
LGLukas Greifenstein
Lukas Greifenstein
VJVivianne Jakobsson
Vivianne Jakobsson
JZJingjing Zhang
Jingjing Zhang

17 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Emil NovruzovEmil Novruzov
Emil Novruzov
Frederik L. GieselFrederik L. Giesel
Frederik L. Giesel
YMYuriko Mori
Yuriko Mori
PCPeter L. Choyke
Peter L. Choyke
MDMardjan Dabir
Mardjan Dabir
LBLeonardo Badinez
Leonardo Badinez
Background: Radiolabeled fibroblast activation protein (FAP) ligands, a novel class of tracers for PET/CT imaging, have demonstrated very promising results in various oncological, as well as in some benign, diseases with long-term potential to supplant the current pan-cancer agent [18F]FDG in some cancer types. Pancreatic ductal carcinoma (PDAC) belongs to the group of epithelial malignancies with a strong so-called “desmoplastic reaction”, leading to a prominent tumor stroma with cancer-associated fibroblasts that exhibit a marked overexpression of fibroblast activation protein (FAP). The first clinical experiences in PDAC with 68Ga-labeled FAP ligands suggested superior sensitivity to [18F]FDG. However, there is limited data with 18F-labeled FAP derivatives, i.e. [18F]FAPI-74, yet prospective single- and multicenter trials are already ongoing. In this proof-of-concept study, we sought to evaluate the biodistribution, tumor uptake, and lesion detectability in patients with PDAC using [18F]FAPI-74 PET/CT as compared to [18F]FDG PET/CT scans for staging. Methods: This study includes 7 patients (median age 69) who underwent both [18F]FDG PET/CT with contrast-enhancement and [18F]FAPI-74 PET with low-dose CT for primary staging (n = 3) and therapy response control after neoadjuvant (n = 1) or re-staging after palliative therapy (n = 3). The mean interval between PET scans was 11 ± 4 days (range 1–15 days). The [18F]FDG and [18F]FAPI-74 PET/CT scans were acquired at 64 ± 4.1 min (range 61–91 min) and 66.4 ± 6.3 min (range 60–76 min), respectively, after administration of 200 ± 94 MBq (range 79–318 MBq) and 235 ± 88 MBq (range 90–321 MBq), respectively. Quantification of tracer uptake was determined with SUVmax and SUVmean. Furthermore, the tumor-to-background ratio (TBR) was derived by dividing the SUVmax of tumor lesions by the SUVmax of adipose tissue, skeletal muscle, and blood pool. Results: Overall, 32 lesions were detected in 7 patients including primary (n = 7), lung (n = 7), bone (n = 3), lymph node (n = 13), and peritoneal metastases (n = 2). [18F]FAPI-74 detected 22% more lesions compared with [18F]FDG with a better TBR and visual lesion delineation. In one patient the primary lesion could be detected unequivocally with [18F]FAPI-74 but was missed by [18F]FDG imaging. Altogether, most of the lesions demonstrated markedly elevated uptake of [18F]FAPI-74 with a simultaneous lower uptake in the background, providing a very high visual contrast. Conclusion: To the best of our knowledge, this is the first, prospective, intra-individual investigation comparing [18F]FAPI-74 with [18F]FDG imaging in PDAC with encouraging results. These pivotalresults supporta larger, multicentric, prospective study to determine the value of [18F]FAPI-74 in detecting and staging PDAC in comparison with current standard of care imaging.

5 June 2025 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
Emil NovruzovEmil Novruzov
Emil Novruzov
GSGabriel T. Sheikh
Gabriel T. Sheikh
EMEduards Mamlins
Eduards Mamlins
AHAdrien Holzgreve
Adrien Holzgreve
YMYuriko Mori
Yuriko Mori
FGFrederik L. Giesel
Frederik L. Giesel
Fibroblast activation protein (FAP)–targeted imaging has emerged as a promising diagnostic tool for various oncologic and nononcologic conditions. However, the increasing employment of FAP-targeted imaging with small-molecule radiotracers mandates a standardized reporting system to ensure consistent interpretation across various clinical scenarios, especially in oncologic imaging. This study proposes an FAP reporting and data system (RADS) framework (FAP-RADS version 1.0) to address those needs, aiming to standardize FAP-targeted imaging reports, improve clinical communication, and support multicenter research. Methods: We conducted a comprehensive literature review and combined the findings with expert consensus in nuclear medicine to design a new scoring system based on the principles of the molecular imaging RADS framework. FAP-RADS version 1.0 is intended for use across multiple tumor types with variable radiotracer uptake patterns and is nonspecific to imaging modality (FAP PET and FAP SPECT) and radiotracer compound structure. We aimed to ensure that the system would be user-friendly and applicable to routine clinical practice. Results: FAP-RADS version 1.0 introduces a 5-point scale to assess the likelihood of malignancy in lesions based on the imaging characteristics of the lesions. The scoring system can be applied to different FAP ligands with varying pharmacokinetics. The framework does not rely on SUV thresholds, making it flexible and robust for clinical use. The implementation of this system aims to improve interdisciplinary communication, support longitudinal follow-up, and facilitate future multicenter trials. Conclusion: The proposed FAP-RADS version 1.0 is a comprehensive and flexible framework that has the potential to enhance the quality and consistency of FAP-targeted imaging interpretation in clinical practice. Its application may lead to better research outcomes, broader acceptance within the oncologic community, and streamlined regulatory processes related to FAP-based radiotracer approval. Visual Abstract

26 December 2025 in Seminars in Nuclear Medicine
Verified
Journal Article
Open access
SSSophie Carina Siegmund
Sophie Carina Siegmund
Emil NovruzovEmil Novruzov
Emil Novruzov
EMEduards Mamlins
Eduards Mamlins
YMYuriko Mori
Yuriko Mori
SOSven Otto
Sven Otto
FGFrederik L. Giesel
Frederik L. Giesel
FAP-ligands as novel cancer radiopharmaceuticals in nuclear medicine have been recently translated successfully into the clinical space. Particularly small molecules (i.e. FAPI-46, FAPI-74) and peptides (i.e. FAP-2286, DOTAGA.SA.FAPi) seem to be some of the most promising molecular probes for imaging and therapy. Back in 2019, there have been slight reservations about adopting this new imaging probe, after the decades of the solidly established role of FDG PET/CT in oncological imaging. At that time, it was expected that these novel ligands might challenge Onco-PET as new cornerstones in the individualized tumor staging and even beyond. However, FAP-targeted imaging is today not intended to replace FDG PET/CT, but rather to complement cancer imaging and therapy, where cancer subtypes exhibit low glucose metabolism which often leads to moderate or very insufficient FDG uptake. Recently, numerous FAP-imaging studies -ranging from single-case reports to larger patient cohorts and even prospective trials have reinforced the empirical understanding of FAP-imaging as a potentially "disruptive" modality compared to FDG PET/CT. The broader application of FAPI PET/CT has gained momentum, shaping a new narrative in oncological imaging and beyond. FAPI PET/CT is now increasingly recognized as a novel imaging agent that does not aim to replace FDG PET/CT, but rather supports it by enhancing diagnostic accuracy in specific sub-cohort of tumor entities, where FDG PET/CT tends to underperform. Several FAP-derivates- such as FAPI-04, FAPI-46, FAPI-74 for PET imaging as well as FAPI-34 for SPECT imaging were rapidly introduced into clinical practice. To date, FAP-imaging agents have steadily paved their way into clinical practice, particularly in tumor entities such as pancreatic ductal adenocarcinoma, gastroesophageal cancers, and hepatocellular carcinoma. Even in lung cancer, where FDG PET/CT has long held a well-established and clinically robust role, FAPI PET/CT has quickly emerged as a strong competitor, especially in case of lung adenocarcinoma. FAPI PET/CT has been gaining increasing acceptance beyond academic and scientific field as a tool for improved oncological imaging, while FAP theranostics is still in the elaboration and early translation. In contrast to imaging probes, FAP-derivates for therapy require a rather long residence (>48 h) time following successful target-binding at the cancer-associated fibroblast or FAP-positive tumor cells to enable the radiotoxic effect (beta- and alpha-emitter) and deliver enough LET to the cancer microenvironment. Meanwhile, FAP-based imaging probes are advancing into the clinical application, with Phase-II/III clinical trials expected as early as Q4/2025 (NCT07217704 & NCT07217717). In contrast, FAP-targeted therapeutics remain in the Phase-I or proof-of-concept stage but brings hope for patients with systemic disease who are left out and urgently need additional innovation drives beyond the standard care. This review article will give insight into the most recent developments in the FAP-Therapeutic applications of cancer treatments using several different promising FAP-derivates to improve FAP-theranostic in oncology.

18 July 2025 in Seminars in Nuclear Medicine
Verified
Journal Article
Open access
Emil NovruzovEmil Novruzov
Emil Novruzov
EMEduards Mamlins
Eduards Mamlins
YMYuriko Mori
Yuriko Mori
JCJens Cardinale
Jens Cardinale
FGFrederik L. Giesel
Frederik L. Giesel
In recent years, FAP-targeted imaging has emerged as a highly-promising modality as a pan-cancer agent. Until now, several studies and review articles have focused on efficacy of FAPI imaging in epithelial malignancies with a high global incidence and prevalence such as lung cancer or GI-tumors. This work sought to shed light on diagnostic performance and clinical impact of FAPI imaging in rather low-incidence tumor-entities, which are nevertheless characterized by a poor outcome.